97 related articles for article (PubMed ID: 8357998)
1. Diphenylmethylazine prostanoids with prostacyclin-like actions on human platelets.
Jones RL; Wilson NH; Marr CG; Muir G; Armstrong RA
J Lipid Mediat; 1993; 6(1-3):405-10. PubMed ID: 8357998
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship between prostacyclin and its platelet receptor. Correlation of structure change and the platelet activity.
Tsai AL; Wu KK
Eicosanoids; 1989; 2(3):131-43. PubMed ID: 2517029
[TBL] [Abstract][Full Text] [Related]
3. [Synthesis and antiaggregation activity of prostacyclin analogs. 1. Bicyclo [3.2.0] heptane analogs].
Lopp MI; Miuraus AI; Parve OV; Vialimiaé TK; Lopp AKh
Bioorg Khim; 1988 Feb; 14(2):222-31. PubMed ID: 3289544
[TBL] [Abstract][Full Text] [Related]
4. (5Z)-carbacyclin displays agonist-antagonist properties on prostacyclin-receptors in platelets and vascular myocytes.
Corsini A; Oliva D; Folco GC; Giovanazzi S; Noe' MA; Fumagalli R; Nicosia S
Biomed Biochim Acta; 1988; 47(10-11):S104-7. PubMed ID: 3073757
[TBL] [Abstract][Full Text] [Related]
5. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids.
Sharif NA; Crider JY; Xu SX; Williams GW
J Pharmacol Exp Ther; 2000 May; 293(2):321-8. PubMed ID: 10772998
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the biological activity of azoprostanoids in human platelets.
Gorman RR; Shebuski RJ; Aiken JW; Bundy GL
Fed Proc; 1981 May; 40(7):1997-2000. PubMed ID: 7014259
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
Meja KK; Barnes PJ; Giembycz MA
Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
[TBL] [Abstract][Full Text] [Related]
8. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.
Jones RL; Qian YM; Wise H; Wong HN; Lam WL; Chan HW; Yim AP; Ho JK
J Cardiovasc Pharmacol; 1997 Apr; 29(4):525-35. PubMed ID: 9156364
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship (SAR) among prostacyclin (PGI2) analogues.
Kovács G; Székely I; Stadler I; Körmöczy P
Acta Physiol Hung; 1984; 64(3-4):225-30. PubMed ID: 6397963
[TBL] [Abstract][Full Text] [Related]
10. Novel 7-oxabicyclo[2.2.1]heptane prostacyclin agonists.
Haslanger MF; Sprague PW; Snitman D; Vu T; Harris DN; Greenberg R; Powell J
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():293-7. PubMed ID: 6221540
[No Abstract] [Full Text] [Related]
11. Synthesis of prostanoids with bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, and bicyclo[2.2.2]octane ring systems. Activities of 15-hydroxy epimers on human platelets.
Wilson NH; Peesapati V; Jones RL; Hamilton K
J Med Chem; 1982 May; 25(5):495-500. PubMed ID: 7086834
[TBL] [Abstract][Full Text] [Related]
12. The antiplatelet activity of immobilized prostacyclin.
Ebert CD; Lee ES; Kim SW
J Biomed Mater Res; 1982 Sep; 16(5):629-38. PubMed ID: 6752148
[TBL] [Abstract][Full Text] [Related]
13. Agonists can discriminate between cloned human and mouse prostacyclin receptors.
Chow KB; Jones RL; Wise H
Prostaglandins Leukot Essent Fatty Acids; 2004 May; 70(5):423-9. PubMed ID: 15062844
[TBL] [Abstract][Full Text] [Related]
14. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.
Whittle BJ; Hamid S; Lidbury P; Rosam AC
Adv Exp Med Biol; 1985; 192():109-25. PubMed ID: 2871707
[No Abstract] [Full Text] [Related]
15. Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic.
Meanwell NA; Rosenfeld MJ; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Seiler SM
J Med Chem; 1992 Jan; 35(2):389-97. PubMed ID: 1370696
[TBL] [Abstract][Full Text] [Related]
16. [Platelet sensitivity to prostacyclin in diabetic and nondiabetic patients with atherosclerotic vascular changes: a measure of platelet membrane prostacyclin receptors?].
Klein K; Kaliman J; Sinzinger H; Silberbauer K
Vasa; 1980; 9(2):123-6. PubMed ID: 6256984
[No Abstract] [Full Text] [Related]
17. Modulation of platelet activation by prostaglandin E2 mimics.
Thierauch KH; Prior G
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():383-6. PubMed ID: 1705385
[No Abstract] [Full Text] [Related]
18. The mechanisms of enhancement and inhibition of field stimulation responses of guinea-pig vas deferens by prostacyclin analogues.
Tam FS; Chan K; Borreau JP; Jones RL
Br J Pharmacol; 1997 Aug; 121(7):1413-21. PubMed ID: 9257922
[TBL] [Abstract][Full Text] [Related]
19. The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells.
Wilkins AJ; MacDermot J
Eur J Pharmacol; 1986 Aug; 127(1-2):117-9. PubMed ID: 2428638
[TBL] [Abstract][Full Text] [Related]
20. [Action of carbacyclic 13,14-didehydro-analogs of prostacyclin on the contractile activity of the rat stomach muscles].
Kobzar' GT; Lopp MI; Lille IuE
Farmakol Toksikol; 1989; 52(3):38-40. PubMed ID: 2507349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
